Loading...
16 antihistamine H1RA COVID-19 controlled studies, 3 RCTs
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ ACCROS-I Valerio-.. (DB RCT) 61% 0.39 [0.24-0.63] no recov. 61 (n) 40 (n) chlorpheniramine Improvement, RR [CI] Treatment Control ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.09-1.24] no recov. 3/61 6/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 89% 0.11 [0.01-0.87] no recov. 1/61 6/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 53% 0.47 [0.22-1.02] no recov. 10/61 14/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.06-1.71] no recov. 2/61 4/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 59% 0.41 [0.14-1.16] no recov. 5/61 8/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 74% 0.26 [0.12-0.58] PASC 55 (n) 46 (n) chlorpheniramine ACCROS-II Valerio-Pascua 54% 0.46 [0.36-0.58] recov. time 330 (n) 330 (n) chlorpheniramine Sanchez-.. (DB RCT) 87% 0.13 [0.01-2.46] hosp. 0/32 2/13 chlorpheniramine Mura (PSM) 25% 0.75 [0.39-1.46] death 88 (n) 88 (n) Salvucci 29% 0.71 [0.51-1.01] PASC 10/14 13/13 LONG COVID CARVIN-II Meiser (DB RCT) 12% 0.88 [0.64-1.20] no recov. 122 (n) 129 (n) CARVIN-II Meiser (DB RCT) 6% 0.94 [0.91-0.96] viral load 122 (n) 129 (n) CARVIN-II Meiser (DB RCT) 2% 0.98 [0.97-0.99] viral load 122 (n) 129 (n) CARVIN-II Meiser (DB RCT) 1% 0.99 [0.98-1.00] viral load 122 (n) 129 (n) CARVIN-II Meiser (DB RCT) 3% 0.97 [0.96-0.98] viral+ 122 (n) 129 (n) Vila‐Corcoles 61% 0.39 [0.12-1.21] cases Hoertel 58% 0.42 [0.25-0.71] death 138 (n) 7,207 (n) hydroxyzine Vila-Córcoles 53% 0.47 [0.22-1.01] cases Reznikov 34% 0.66 [0.58-0.75] cases n/a n/a Reznikov 37% 0.63 [0.44-0.90] cases n/a n/a Reznikov 17% 0.83 [0.62-1.12] cases n/a n/a Reznikov 48% 0.52 [0.16-1.64] cases n/a n/a Reznikov 52% 0.48 [0.34-0.67] cases n/a n/a Reznikov 43% 0.57 [0.42-0.78] cases n/a n/a Reznikov 62% 0.38 [0.11-1.32] cases n/a n/a Reznikov -33% 1.33 [0.50-3.57] cases n/a n/a Reznikov 34% 0.66 [0.48-0.89] cases n/a n/a Reznikov 26% 0.74 [0.55-0.99] cases n/a n/a Reznikov 35% 0.65 [0.52-0.79] cases n/a n/a Reznikov 14% 0.86 [0.71-1.05] cases n/a n/a Reznikov 74% 0.26 [0.07-1.01] cases n/a n/a Reznikov 78% 0.22 [0.05-1.00] cases n/a n/a Reznikov 36% 0.64 [0.33-1.25] cases n/a n/a Reznikov 8% 0.92 [0.47-1.75] cases n/a n/a Reznikov 59% 0.41 [0.25-0.68] cases n/a n/a Reznikov 29% 0.71 [0.44-1.15] cases n/a n/a McKeigue -30% 1.30 [1.13-1.51] severe case case control Sánchez-Rico 46% 0.54 [0.31-0.89] death 18/164 1,571/14,939 hydroxyzine Monserrat .. (PSM) 80% 0.20 [0.02-0.93] death n/a n/a loratadine Hunt 43% 0.57 [0.49-0.66] death 260/7,600 1,352/18,908 Loucera 40% 0.60 [0.43-0.84] death 251 (n) 15,717 (n) Loucera 30% 0.70 [0.48-1.00] death 251 (n) 15,717 (n) Loucera 51% 0.49 [0.32-0.77] death 233 (n) 15,735 (n) Hoertel -7% 1.07 [0.88-1.31] death 962 (n) 4,810 (n) desloratadine/hydroxyzine Hoertel 8% 0.92 [0.49-1.76] death 11/94 62/470 desloratadine/hydroxyzine Hoertel -9% 1.09 [0.89-1.35] death 104/962 591/4,810 desloratadine/hydroxyzine Antihistamine H1RA COVID-19 outcomes c19 earlyDecember 2024 Favors H1RAs Favors control
Figure S2. Comparison of results for RCTs versus observational studies.
For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
